StockData

Artiva Biotherapeutics vs Celldex Therapeutics

ARTV and CLDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARTV and CLDX compare

Celldex Therapeutics is the larger company, worth 12 times as much as Artiva Biotherapeutics ($2.3B against $196M).

Artiva Biotherapeutics scores higher on the StockData Score (8 against 7 for Celldex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARTVCLDX
Size and price
Market cap$196M$2.3B
Share price$4.01$28.83
Change, 1 year0.75%18.9%
Change, 5 years–−32.9%
Beta (5Y)2.301.32
Employees104198
StockData Score
Total score8 (better)7
Valuation score1 (better)0
Growth score00
Performance score11
Health score66
Dividend score00
Valuation
P/S–14329×
P/B0.6× (better)3.5×
FCF yield−44.2%−11.5% (better)
Growth
Revenue growth (TTM)–−93.9%
Revenue growth, 5Y average–−26.9%
Profitability
Operating margin–−211685%
Net margin–−195609%
FCF margin–−164392%
Return on equity−43.6% (better)−49.5%
Return on invested capital−2120% (better)−3698%
Financial health
Debt / equity0.000.00
Current ratio19.88 (better)10.97
Altman Z-score3.6914.36 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions83.2%109%
Held by insiders68.3%0.41%
Insider net buying, 12 months$106M (better)−$121K
Superinvestors holding1–
Short interest, % of float19.0%12.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.